Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398620 | 0.82 | SCN4A (0.46) | SCN4ATACR1 | |
| SCHEMBL12270763 | 0.77 | EPHX1 (0.55) | EPHX1SCN4AANPEPTACR1MMP2 | |
| SCHEMBL2407513 | 0.74 | CYP1A2 (0.53) | TAAR1SLC6A4SLC6A3LTA4H | |
| SCHEMBL2399043 | 0.71 | CYP1A2 (0.34) | SLC6A4SLC6A3 | |
| SCHEMBL2399759 | 0.70 | DRD4 (0.45) | MAOASIGMAR1 | |
| SCHEMBL12266460 | 0.70 | TACR1 (0.50) | EPHX1SCN4AANPEPTACR1MMP2 | |
| SCHEMBL12266457 | 0.69 | SCN4A (0.44) | EPHX1SCN4AANPEPTACR1SLC6A2 | |
| SCHEMBL2399715 | 0.68 | HTR2A (0.49) | SLC6A2SLC6A4SLC6A3LTA4H | |
| SCHEMBL2398439 | 0.68 | HTR2A (0.42) | SLC6A2TAAR1SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL2398986 | 0.68 | SCN4A (0.47) | EPHX1SCN4AANPEPTACR1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | claimed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | claimed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | claimed |
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | EPHX1 3816/4885SCN4A 2539/4885ANPEP 635/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | EPHX1 4646/4885SCN4A 240/4885ANPEP 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.